Sugi Predict

Sugi Predict / Compounds / SCHEMBL1783911

SCHEMBL1783911

SCHEMBL1783911

COc1ccc(Cn2nnnc2CN)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.61
▸ PKM P14618 1/20 0.61
▸ GAA P10253 4/20 0.56
▸ TSHR P16473 3/20 0.56
▸ ALOX15 P16050 2/20 0.56
▸ POLB P06746 1/20 0.55
▸ L3MBTL1 Q9Y468 2/20 0.49
▸ LMNA P02545 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ ERCC5 P28715 1/20 0.46
▸ FEN1 P39748 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ HTT P42858 2/20 0.44
▸ PDE8B O95263 1/20 0.43
▸ TOP2A P11388 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7148471 0.86 ALDH1A1 (0.62) ALDH1A1PKMGAATSHRALOX15
SCHEMBL1768275 0.85 SMN1; SMN2 (0.48) ALDH1A1PKMGAATSHRALOX15
SCHEMBL3735937 0.85 ALDH1A1 (0.64) ALDH1A1PKMGAATSHRALOX15
SCHEMBL1768224 0.83 ALDH1A1 (0.54) ALDH1A1PKMGAATSHRALOX15
SCHEMBL25218986 0.82 ALDH1A1 (0.62) ALDH1A1PKMGAATSHRALOX15
SCHEMBL6501472 0.80 ALDH1A1 (0.59) ALDH1A1PKMGAATSHRALOX15
SCHEMBL24033865 0.80 ALDH1A1 (0.59) ALDH1A1PKMGAATSHRALOX15
SCHEMBL7684043 0.80 ALDH1A1 (0.54) ALDH1A1PKMGAATSHRALOX15
SCHEMBL19732308 0.80 ALDH1A1 (0.54) ALDH1A1PKMGAATSHRALOX15
SCHEMBL15796733 0.79 ALDH1A1 (0.58) ALDH1A1PKMGAATSHRALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2735561-B1 Substituted carbamoylmethoxyacetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2016-07-20 — — EP disclosed
EP-2640375-B1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2016-05-18 — — EP disclosed
US-8993631-B2 Method of treating contrast-induced nephropathy NOVARTIS AG (CH) 2015-03-31 — — US disclosed
US-20140336194-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2014-11-13 — — US disclosed
US-8877786-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-11-04 — — US disclosed
EP-2735561-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors Novartis AG (CH) 2014-05-28 — — EP disclosed
EP-2501683-B1 SUBSTITUTED CARBAMOYLMETHYLAMINO ACETIC ACID DERIVATIVES AS NOVEL NEP INHIBITORS NOVARTIS AG (CH) 2014-04-23 — — EP disclosed
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-03-27 — — US disclosed
US-8642635-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2014-02-04 — — US disclosed
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-04-18 — — US disclosed
US-8377978-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2013-02-19 — — US disclosed
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-08-09 — — US disclosed
US-8222286-B2 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2012-07-17 — — US disclosed
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY NOVARTIS AG (CH) 2012-05-17 — — US disclosed
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors NOVARTIS AG (CH) 2011-05-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140088165-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 176/4885PKM 2191/4885GAA 172/4885
US-20140336194-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY REN, SERPINB1, MME ALDH1A1 2474/4885PKM 3580/4885GAA 427/4885
US-20130096168-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 176/4885PKM 2191/4885GAA 172/4885
US-20120122844-A1 METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY REN, SERPINB1, MME ALDH1A1 2474/4885PKM 3580/4885GAA 427/4885
US-20120202862-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 176/4885PKM 2191/4885GAA 172/4885
US-20110124695-A1 Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors MME, REN, AGTR1 ALDH1A1 175/4885PKM 2205/4885GAA 168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.